Expand IFRX Menu
IFRX MENU

IFRX Latest Press Releases

-- August 20, 2026 --

InflaRx Announces Participation in September Investor Conferences Globe Newswire 7:30 AM

-- August 6, 2026 --

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones Globe Newswire 7:30 AM

-- July 30, 2026 --

InflaRx to Report Second Quarter 2026 Results on August 6, 2026 Globe Newswire 7:30 AM

-- June 30, 2026 --

InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos Globe Newswire 7:30 AM

-- May 8, 2026 --

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares Globe Newswire 8:15 AM

-- May 6, 2026 --

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares Globe Newswire 8:30 AM
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases Globe Newswire 8:25 AM

-- May 4, 2026 --

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes Globe Newswire 7:30 AM

-- May 1, 2026 --

InflaRx to Report First Quarter 2026 Results on May 7, 2026 Globe Newswire 7:30 AM

-- April 28, 2026 --

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement Globe Newswire 7:30 AM

-- April 9, 2026 --

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor Globe Newswire 7:30 AM

-- March 31, 2026 --

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium Globe Newswire 7:30 AM

-- March 30, 2026 --

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes